Next Quarterly Earnings
Monday, December 14, 2026
CW 51
Pre-Market
In 62 days
Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
Abivax
Abivax is a French biopharmaceutical company specializing in the development of innovative therapeutics for the treatment of chronic inflammatory diseases. Through its clinical research, Abivax specifically addresses significant unmet medical needs in the treatment of ulcerative colitis.
Recap: the latest results
Abivax (ABVX) released its Q2 2026 earnings results on September 21, 2026, after market close. The company reported an EPS of -1.47 EUR, missing the analyst estimate of -0.80 EUR by 83.5%. Revenue was reported at 1 million EUR. Following the release, the stock price decreased by 4.69%.
Generated automatically from our data — as of 09/30/2026 Read the article →
Frequently asked questions
When will Abivax report its next quarterly earnings?
Abivax is scheduled to report its next quarterly earnings on 12/14/2026. Pre-market — typically early morning before trading starts (around 7–8 a.m. CET).
When did Abivax last report quarterly earnings?
Abivax last reported quarterly earnings on 9/21/2026 (Q2 2026). Earnings per share (EPS) came in at -1.47 EUR.
How does Abivax stock react to earnings?
Across its last 3 earnings reports, Abivax stock moved by ±5.7% on average the following day. The largest reaction was +8.7% on 05/22/2026; 1 of 3 reactions were positive.
How often has Abivax beaten expectations?
Abivax has beaten analyst EPS estimates in 2 of its last 5 evaluated quarters (beat rate: 40%).
How do I add the Abivax earnings dates to my calendar?
Use the 'Subscribe in calendar' button on this page to add all dates to Google Calendar, Apple Calendar or Outlook. Dates update automatically when they change.
In the earnings calendar
Earnings statistics
Stock reaction to earnings
±5.7%
Avg. next-day move
+8.7%
Largest move (05/22/2026)
33.3%
Share of positive reactions
±8.9%
Avg. move after 7 days
Basis: price reactions to the last 3 report dates (close to close).
Estimates vs. results
2/5
Quarters above estimates
40%
Beat rate
-9.5%
Avg. EPS surprise
Basis: 5 quarters with an analyst estimate and reported EPS.
Past price reactions are not a reliable indicator of future performance.
Company Information
Name
Abivax
Country
🇫🇷
More Financial Information